|Bid||0.01 x 1100|
|Ask||5.82 x 800|
|Day's Range||4.84 - 5.12|
|52 Week Range||4.61 - 14.29|
|Beta (3Y Monthly)||0.94|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
MELBOURNE, Australia, April 30, 2019 -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral.
MELBOURNE, Australia, April 17, 2019 -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral.
Every investor in Immuron Limited (ASX:IMC) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller comp...
Key Highlights: Immuron achieved 66% YoY growth in worldwide sales for the third quarter of FY19, ending March 31, 2019.In Australia Q3 sales of Travelan® surged ahead, growing.
C. difficile remains a major medical problem, causing an estimated annual economic burden of more than USD $10 billion globally, with 28,000 deaths per year in the U.S..
Key Points Immuron to develop U.S. registration dossier for IMM-124E for Travelers’ DiarrheaCompany anticipates significant inflection in sales with successful FDA registration.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! The direct benefit for Immuron Limited (ASX:IMC),Read More...
Key Highlights: Immuron achieved 7% YoY growth in worldwide sales for the first half of FY19.In the US, Travelan® exhibited double-digit growth for this period, with sales 10%.
MELBOURNE, Australia, Jan. 08, 2019 -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the “Company”) is pleased to announce that under the Australian Government’s Research and.
If you own shares in Immuron Limited (ASX:IMC) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of Read More...
NASDAQ: IMRN), is pleased to announce the appointment of Gary S. Jacob as Chief Executive Officer. Dr Jacob is the former Chairman, President and Chief Executive Officer of Synergy Pharmaceuticals Inc. a Nasdaq-listed public biopharmaceutical company located in New York, NY focused on the development of drugs to treat gastrointestinal disorders and diseases.
Australian Travelan® sales continue to grow, with a Q1 CY19 figure of $340K AUD. Global Immuron Limited sales for Q1 2019 reached $482K AUD which is a 2% increase on the same quarter of last financial year. NASDAQ: IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of many gut mediated diseases, today announced that the IMM-124E NASH clinical study findings will be presented by Professor Arun Sanyal at the American Association for the study of Liver Disease which will be held in San Francisco, California during the 9th – 13th of November 2018.
If you want to know who really controls Immuron Limited (ASX:IMC), then you’ll have to look at the makeup of its share registry. Institutions will often hold stock in biggerRead More...